The bidding window for Silky Overseas SME IPO was open from June 30, 2025, to July 2, 2025, during which the IPO received 18,98,20,000 bids against a total of 19,05,600 shares offered. The basis of allotment will be finalised today, July 3, 2025. Here’s how you can check the IPO allotment status.
Silky Overseas IPO is a book-building issue of ₹30.68 crores, consisting entirely of a fresh issue of 19.06 lakh equity shares. The price band is set at ₹161 per share. The tentative listing on NSE Emerge is scheduled for July 7, 2025.
Gretex Corporate Services Limited is the book-running lead manager, and Skyline Financial Services is the registrar for the issue.
Click here to explore other Upcoming IPOs
The net proceeds from the fresh issue will be used towards:
(July 2, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
62.99 |
Non-Institutional Investors |
430.21 |
Retail Individual Investors(RIIs) |
119.34 |
Total |
169.93 |
Click here to check out newly Listed IPOs
As of 3 July 2025, Silky Overseas IPO’s GMP stood at ₹45. The estimated listing price is ₹206, i.e., a 27.95% gain per share over the upper price band.
Source: Business Standard Report dated 3 July, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Silky Overseas manufactures and supplies high-quality bedding essentials, with a core focus on products such as blankets, bed sheets, comforters, curtains, and baby blankets under the in-house brand Rian Décor.
The entire production cycle is managed in-house, including knitting, dyeing, processing, printing, and packaging.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here